

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT NOV 9 2006 (Use as many sheets as necessary)		Application Number	10/686,808
		Filing Date	October 16, 2003
		First Named Inventor	Steven K. Burke
		Art Unit	1618
		Examiner Name	Schlientz, Leah H.
Sheet	1	of	1
		Attorney Docket Number	438.1 US

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

Examiner Signature Date Considered 11-29-06

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ² Applicant's unique citation designation number (optional). ³ See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 801.04. ⁴ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁵ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁶ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁷ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Substitute for form 1449B/PTO				Complete if Known	
				Application Number	10/686,808
				Filing Date	October 16, 2003
				First Named Inventor	Steven K. Burke
				Art Unit	1618
				Examiner Name	Schlientz, Leah H.
Sheet 2		of 2	Attorney Docket Number 438.1		

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T ²
<i>SKB</i>		CHERTOW, G.M., BURKE, S.K., LAZARUS, J.M., STENZEL, K.HL, WOMBOLT, D., GOLDBERG, D., BOVENTRE, J.V., AND SLATOPOLSKY, E., "Poly(allylamine hydrochloride) (RenaGel®): a noncalcemic phosphate binder for the treatment of hyperphosphatemia in chronic renal failure", Am. J. Kid. Dis. 29: 66-71 (1997)		
		GOLDBERG, D.I., DILLON, M.S., SLATOPOLSKY, E.A. GARRETT, B., GRAY, J.R., MARBURY, T., WEINBERG, M., WOMBOLT, D., AND BURKE, S.K., "Effect of RenaGel, a non-absorbed, calcium-and aluminum-free phosphate binder, on serum phosphorus, calcium, and intact parathyroid hormone in end-stage renal disease patients," Nephrol Dial Transplant 13: 2303-2310 (1998)		
		CHERTOW, G.M., DILLON, M., BURKE, S.K. STEG, M., BLEYER, A.J. GARRETT, B.N., DOMOTO, D.T., WILKES, B.M., WOMBOLT, D.G., AND SLATOPOLSKY, E., "A randomized trial of sevelamer hydrochloride (RenaGel®) with and without supplemental calcium. Strategies for the control of hyperphosphatemia in hemodialysis patients," Clin Nephrol. 51: 18-26 (1999)		
		BLEYER, A.J., BURKE, S.K., DILLON, M., GARRETT, B., KANT, K.S., LYNCH, D., RAMAN, S.N. SHOENFELD, P., TEITELBAUM, I., ZIEG, S., AND SLATOPOLSKY, E., "A comparison of the calcium-free phosphate binder sevelamer hydrochloride with calcium acetate in the treatment of hyperphosphatemia in hemodialysis patients," Am. J. Kid. Dis. 33: 694-701 (1999)		
		SLATOPOLSKY, E., BURKE, S.K., DILLON, M.A. AND THE RENAGEL STUDY GROUP, "RenaGel®, a nonabsorbed calcium and-aluminum-free phosphate binder, lowers serum phosphorus and parathyroid hormone," Kidney Int. 55: 299-307 (1999)		
		CHERTOW, G.M., BURKE, S.K., DILLON, M.A., AND SLATOPOLSKY, E. FOR THE RENAGEL STUDY GROUP, "Long-term effects of sevelamer hydrochloride on the calcium x phosphorus product and lipid profile of haemodialysis patients," Nephrol Dial. Transplant. 14: 2907-2914 (1999)		
		CHERTOW, G.M., BURKE, S.K., RAGGI, P., FOR THE TREAT TO GOAL WORKING GROUP, "Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients," Kidney Int. 62: 245-252 (2002)		
Declaration of Melissa Pilon under 37 C.F.R. §1.132 <i>Do not print, just sign</i>				

Examiner Signature	<i>Leah Schlientz</i>	Date Considered	11-29-06
--------------------	-----------------------	-----------------	----------

*EXAMINER initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P. O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.